cqvip:Background. A 63-year-old man with therapy-resistant Se′ zary syndrome was enrolled in a multicenter trial of oral bexarotene for advanced-stage cutaneous T-cell lymphoma(CTCL). Methods. Monthly evaluations for efficacy and side-effects were conducted and documented. Results. Gradual improvement in erythema, pruritus, and scale was noted during the initial 16week trial period and treatment was extended to 40 weeks. From week 20 to week 40, the erythroderma continued to improve and the lymph node burden decreased, but the absolute Se′ zary cell count inversely increased. By week 40, intractable pruritus and erythroderma abruptly recurred, and bexarotene was discontinued. Conclusions. Bexarotene is well tolerated and can be efficacious in patients with Se′ zary syndrome. Shifting of Se′ zary cells between different compartments was noted. Further studies on the interaction between the skin, lymph nodes, and peripheral blood compartments during bexarotene treatment in this subset of patients with CTCL are needed.
展开▼
